The Department of Health and Social Care asked the National Institute for Health and Care Excellence (NICE) to produce guidance on using ocrelizumab, also known as Ocrevus, in the NHS in England...
Our news web pages include ground-breaking multiple sclerosis news and research from around the world.
These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.
Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.
We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years.
The Department of Health and Social Care asked the National Institute for Health and Care Excellence (NICE) to produce guidance on using ocrelizumab, also known as Ocrevus, in the NHS in England...
The US Food and Drug Administration (FDA) recently cleared the myBioness mobile app for use with the Bioness L300 Go System, an FES (Functional Electrical...
A new project aimed at investigating the role of muscarinic type 3 receptors (M3R) in myelination and determining their potential as targets in treating multiple sclerosis (MS) recently won $1.7...
A certain type of pain-relief given during childbirth does not increase the risk of women with multiple sclerosis (MS) having relapses after giving birth, a European study reports. The study...
An interactive, psychotherapy-based online programme called “Elevida” can reduce fatigue in multiple sclerosis (MS) patients, according to a clinical study published in the Journal of Neurology,...
Two recent PatientsLikeMe studies have shed new light on the patient experience with health care in America and show that while opinions about care and provider performance vary according to...
It’s been just over six months since NHS England made cladribine (Mavenclad) available to patients with highly-active relapsing remitting multiple sclerosis (RRMS) in England, but according to a...
A new study, published in the journal Neurology, has linked psychiatric conditions, such as depression, anxiety...
Results from the CHANGE-MS phase 2b study of GNbAC1 have shown that GNbAC1 administration has a significant, consistent positive...
A recent study of siponimod has highlighted the drug as the first potential therapy to meaningfully delay disability progression in secondary progressive MS (SPMS) patients.
Full results...